Donate
Make an Impact

What can we help you find?

Pre-Clinical Testing of an Optimised Gene Therapy for the Treatment of Epilepsy

Pre-Clinical Testing of an Optimised Gene Therapy for the Treatment of Epilepsy

Grants Awarded
LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77K Per Patient Over Five Years

LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77K Per Patient Over Five Years

ResearchLivaNova says a new cost analysis found that Vagus Nerve Stimulation Therapy (VNS Therapy) System results in lower resource utilization and lower cost for drug-resistant epilepsy patients when compared to continued treatment with anti-epileptic drugs.

Sense of Control, Selective Attention, Cognitive Inhibition, and Psychosocial Outcomes after Retraining and Control Therapy (ReACT) in Pediatric Functional Seizures

ResearchDifferences in sense of control, cognitive inhibition, and selective attention in pediatric functional seizures (FS) versus matched controls implicate these as potential novel treatment targets. Retraining and Control Therapy (ReACT), which targets these factors, has been shown in a randomized controlled trial to be effective in improving pediatric FS with 82% of patients having complete symptom remission at 60 days following treatment.

Efficacy and Safety of Ketogenic Dietary Therapies in Infancy. A Single-Center Experience in 42 Infants Less Than Two Years of Age

ResearchKetogenic dietary therapies are useful and effective treatments in infancy. Side effects are frequent but mild and easy to manage.

Gene Therapy for Epilepsy Shows Promise in Animal Models

ResearchA new gene therapy concept has been developed for the treatment of temporal lobe epilepsy.

Global Registry Launched On Vagus Nerve Stimulation Therapy For Patients With Drug-resistant Epilepsy

ResearchA new system of vagus nerve stimulation (VNS) therapy was implanted in the first patient with drug-resistant epilepsy, as part of a global registry launched by LivaNova to evaluate the treatment in a real-world setting.

Long Term Outcomes After New-Onset Refractory Status Epilepticus (NORSE): Treatment with Vagus Nerve Stimulation

ResearchThe current evidence supporting the use of vagus nerve stimulation in patients with therapy resistant epilepsy after new-onset refractory status epilepticus warrants further investigation.The current evidence supporting the use of vagus nerve stimulation in patients with therapy resistant epilepsy after new-onset refractory status epilepticus warrants further investigation.

Expert Consensus Opinions Published in Neurology and Therapy Discuss Adjustment of Anti-Seizure Medication Dosing for Optimal Care

ResearchFeaturing the work of CURE Epilepsy grantee Dr. Pavel Klein. Consensus opinions report that lowering the doses of certain anti-seizure medications (ASMs) when beginning treatment with XCOPRI® (cenobamate tablets) CV may help manage possible side effects. SK Life Science, Inc. announced the publication in the journal Neurology and Therapy.

Neurostimulation in People with Drug-Resistant Epilepsy: Systematic Review and Meta-Analysis from the ILAE Surgical Therapies Commission

ResearchNeurostimulation modalities are an effective treatment option for drug resistant epilepsy, with improving outcomes over time and few major complications. Seizure reduction rates among the three therapies were similar during the initial blinded phase.

Developing Precision Medicine Treatments for Genetic Epilepsies: Present Challenges, Recent Scientific Advances, and Future Prospects

DiscoveryProgress stemming from this call to action could bring a new age of treatments for those with epilepsy, shifting from observational experience to data-driven and patient-centered precision therapy.
1 2 3 4 5 … 14